A CHANGE IN GUT MICROBIOTA PARAMETERS ACCORDING TO THE CHARACTERISTICS OF THE COURSE OF THE TUBERCULOSIS PROCESS

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The paper gives the results of an investigation of the gut microbiota in patients with new-onset pulmonary tuberculosis (TB) according to the characteristics of the course of the tuberculosis process. The investigation enrolled 71 patients (37 (52.1%) males and 34 (47.9%) females) with new-onset respiratory TB diagnosed less than one month before their inclusion in the investigation and with no history of autoimmune diseases, cancers, HIV infection, viral hepatitis, alcoholism, drug addiction, or pregnancy. A control group consisted of 27 healthy volunteers. The patients’ age was 18-59 years. The gut microbiota was studied using a bacteriological assay of native feces before treatment. It was found that a decreased normal intestinal microflora level was less frequently observed in patients with focal TB and pulmonary tuberculomas. With the aggravation of the tuberculous process (infiltrative, disseminated and fibrocavernous TB), the frequency and magnitude of the reduced level of normal intestinal microflora substantially increased in patients. There was a more significant frequency and magnitude of the decreased level in the normal intestinal microflora (Bifidobacterium, Lactobacillus, typical Escherichia coli, and Enterococcus) in patients with the extent of the process affecting >2 lobes of the lung than on those with the process in the < 2 lobes. A reduced level of normal microflora (Lactobacillus, typical E. coli and Enterococcus) was more frequently observed in the presence of bacterial excretion. With enhanced bacterial excretion, the number of patients with the reduced level of Bifidobacterium and typical E. coli levels also increased. At the same time, there was no relationship between the frequency and magnitude of a decrease in the normal intestinal microflora and the spectrum of drug resistance of Mycobacterium tuberculosis.

全文:

受限制的访问

作者简介

O. Komissarova

Central Research Institute of Tuberculosis, Ministry of Education and Science of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: rizvan0403@yandex.ru

Professor, MD

俄罗斯联邦,

V. Shorokhova

Central Research Institute of Tuberculosis, Ministry of Education and Science of Russia

Email: rizvan0403@yandex.ru
俄罗斯联邦,

R. Abdullaev

Central Research Institute of Tuberculosis, Ministry of Education and Science of Russia

Email: rizvan0403@yandex.ru

Professor, MD

俄罗斯联邦,

S. Andreevskaya

Central Research Institute of Tuberculosis, Ministry of Education and Science of Russia

编辑信件的主要联系方式.
Email: rizvan0403@yandex.ru

Candidate of Medical Sciences

俄罗斯联邦,

参考

  1. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.
  2. Цыгина Т.Ю. Совершенствование комплексного лечения больных инфильтративным туберкулезом легких с множественной и широкой лекарственной устойчивостью возбудителя при дисбиозе толстой кишки. Автореф. дис.. канд. мед. наук. М., 2010; 29 с.
  3. Eribo O.A. Plessis N., Ozturk M. et al. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty? Cell Mol Life Sci. 2020; 77 (8): 1497-509. doi: 10.1007/s00018-019-03370-4
  4. Luo M., Liu Y., Wu P. et al. Alternation of Gut Microbiota in Patients with Pulmonary Tuberculosis. Front Physiol. 2017; 8: 822. doi: 10.3389/fphys.2017.00822
  5. Khan N. Vidyarthi, A., Nadeem, S. et al. Alteration in the gut microbiota provokes susceptibility to tuberculosis. Front Immunol. 2016; 7: 529. doi: 10.3389/fimmu.2016.00529
  6. Голошубина В.В., Трухан Д.И., Багишева Н.В. Нарушения кишечного микробиоценоза: актуальные аспекты терминологии, клиники, профилактики. РМЖ. 2020; 12: 17-22.
  7. Кожевников А.А., Раскина К.В., Мартынова Е.Ю. и др. Кишечная микробиота: современные представления о видовом составе, функциях и методах исследования. РМЖ. 2017; 17: 1244-7.
  8. Wu H.J. Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012; 3: 4-14. doi: 10.4161/gmic.19320
  9. Schirmer M., Smeekens S.P., Vlamakis H. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. 2016; 167 (4): 1125-1136.e8. DOI: 10.1016/j. cell.2016.10.020

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. The prevalence of reduced gut microbiota levels in patients with new-onset TB according to the clinical forms of TB

下载 (57KB)
3. Fig. 2. The occurrence of a reduced level in intestinal microbiota parameters in patients with new-onset TB according to the extent of the tuberculosis process

下载 (43KB)
4. Fig. 3. The prevalence of a reduced level in gut microbiota parameters in patients with new-onset TB according to the presence/absence of bacterial excretion

下载 (40KB)
5. Fig. 4. The prevalence of a reduced level in gut microbiota parameters in patients with new-onset TB according to the presence of tuberculous intoxication

下载 (41KB)

版权所有 © Russkiy Vrach Publishing House, 2022